Targeting Akt in cancer for precision therapy

Table 2 Active or completed phase III clinical trials of Akt inhibitors

Trial ID	Official title	Akt inhibitor	Combination	Cancer type	Phase	Molecular markers	Estimated enrollment
NCT03997123	CAPItello-290	Capivasertib	Paclitaxel	TNBC	III	ER⁻/PR⁻/HER2⁻	924
NCT04862683	CAPItello-292	Capivasertib	Fulvestrant Palbociclib	Locally advanced or metastatic breast cancer	III	HR⁺/HER2⁻	628
NCT04305496	CAPItello-291	Capivasertib	Fulvestrant	Locally advanced or metastatic breast cancer	III	HR⁺/HER2⁻	834
NCT04493853	CAPItello-281	Capivasertib	Abiraterone	Hormone sensitive prostate cancer	III	AR	1000
NCT03072238^a	IPATential150	Ipatasertib	Abiraterone Prednisolone	Metastatic prostate cancer	III	PTEN	1101
NCT03337724	IPATunity130	Ipatasertib	Paclitaxel	Locally advanced or metastatic breast cancer	III	PIK3CA/AKT1/PTEN ER⁻/PR⁻/HER2⁻HR^+/HER2⁻	580
NCT04060862	IPATunity150	Ipatasertib	Fulvestrant Palbociclib	Locally advanced or metastatic breast cancer	III	HR⁺’HER2⁻	N.A
NCT04650581	FINER	Ipatasertib	Fulvestrant	Advanced breast cancer following progression on first-line CDK4/6 inhibitor and aromatase inhibitor	III	ER⁺/HER2⁻	250
NCT04177108	N.A	Ipatasertib	Atezolizumab Paclitaxel	Locally advanced or metastatic breast cancer	III	ER⁻/PR⁻/HER2⁻	242^b

ISSN: 1756-8722